Lupin is the exclusive first-to-file for this product and may be eligible to receive a 180-day exclusivity. Raltegravir ...

Drugmaker Lupin aims to be part of the first wave of generic drugmakers to make GLP-1 receptor agonists products, used to ...

The company posted a net profit of Rs 852.6 crore in the quarter ended September in comparison to Rs 489.7 crore in the ...

(Photo: Company Website) Global pharma major Lupin Limited on Tuesday announced the launch of the first generic version of Pred Forte (Prednisolone Acetate) Ophthalmic Suspension USP, 1% in the ...

Lupin Q2 Results Live : Lupin declared their Q2 results on November 7, 2024, reporting a robust performance with a topline ...

Global pharma major Lupin Limited on Friday announced that it has received tentative approval from the United States Food and ...

Lupin receives US FDA tentative approval for raltegravir tablets, USP: Our Bureau, Mumbai Friday, November 8, 2024, 17:45 Hrs [IST] Global pharma major Lupin Limited (Lupin) annou ...

Lupin’s average revenue will potentially increase 9.2 per cent Y-o-Y to Rs 5,502 crore as against Rs 5,038 crore in Q2FY24.

Global pharma major Lupin Limited (Lupin) announced the launch of the first generic version of Pred Forte (prednisolone acetate) ophthalmic suspension USP, 1% in the United States. Being the first ...

CEO Vinita Gupta stated that Lupin expects to maintain a quarterly range of $220-230 million for its US business, driven by ...

Food engineers have harnessed the power of lupins (legumes) to create a yogurt that rivals dairy in taste and texture while ...

Lupin Ltd (BOM:500257) reports robust financial performance with significant gains in India and US markets, while navigating competitive challenges and FDA compliance issues.